MSI Testing Market - Strategic Insights and Forecasts (2026-2035)

The MSI Testing Market is expected to grow at a CAGR of 8.5% from a market value of USD 601.1 million in 2026 to USD 1,253.5 million in 2035.

The MSI testing market comprises molecular diagnostic products and services that detect alterations in microsatellite regions resulting from deficient DNA mismatch repair mechanisms. MSI status serves as a predictive biomarker for immunotherapy response and provides valuable information for hereditary cancer assessment, particularly in patients suspected of having Lynch syndrome. The market occupies a central position within precision oncology, where treatment selection increasingly depends on molecular characteristics rather than tumor location alone.

Clinical practice is increasingly shifting toward comprehensive genomic profiling because oncologists require multiple biomarkers from a single patient specimen before initiating targeted therapy. This transition is increasing demand for MSI assays that integrate seamlessly with broader molecular testing workflows, reducing tissue consumption while improving diagnostic efficiency. Laboratories consequently prefer validated kits, automated instruments, and bioinformatics solutions capable of delivering standardized results across diverse healthcare settings.

Pharmaceutical sponsors continue incorporating MSI status into oncology development programs because biomarker-enriched clinical trials improve patient selection and strengthen therapeutic evidence. This strategy is expanding the role of companion diagnostics beyond regulatory approval, making diagnostic manufacturers strategic collaborators throughout clinical development. As immunotherapy indications continue broadening across solid tumors, demand for clinically validated MSI assays is extending into community hospitals and regional pathology laboratories in addition to academic cancer centers.

Regulatory frameworks increasingly emphasize analytical validity, clinical performance, and standardized reporting for molecular diagnostics. These requirements are encouraging manufacturers to invest in assay harmonization, automation, and quality assurance while healthcare systems continue integrating molecular diagnostics into national precision medicine initiatives. The resulting ecosystem supports sustained innovation across PCR, NGS, immunohistochemistry correlation, and software-enabled interpretation platforms.

Market Dynamics

Market Drivers

• Increasing Adoption of Biomarker-Guided Immunotherapy: Immune checkpoint inhibitors increasingly rely on molecular biomarkers that identify patients most likely to achieve durable clinical responses. Oncology practices are consequently incorporating MSI testing into routine diagnostic pathways before initiating immunotherapy. This dependency strengthens demand for highly standardized molecular assays because treatment eligibility directly depends on biomarker accuracy.

• Expansion of Precision Oncology Clinical Trials: Precision oncology increasingly depends on genomic biomarkers to improve patient stratification and therapeutic outcomes. Pharmaceutical sponsors are incorporating MSI testing throughout early- and late-stage oncology trials because genetically selected populations strengthen clinical evidence. This approach reduces patient heterogeneity while supporting more efficient regulatory submissions. Diagnostic companies are responding through collaborative assay development and multicenter clinical validation studies.

• Growing Adoption of Comprehensive Genomic Profiling: Cancer management increasingly requires simultaneous evaluation of multiple biomarkers rather than sequential single-gene testing. Laboratories are adopting NGS workflows that integrate MSI assessment alongside tumor mutational burden and actionable genomic variants. This consolidation improves tissue utilization while reducing testing turnaround time. Manufacturers continue developing integrated reagent kits and software platforms that simplify genomic interpretation.

• Regulatory Support for Companion Diagnostics: Regulatory agencies recognize molecular diagnostics as essential components of personalized oncology. Manufacturers are pursuing companion diagnostic approvals because regulatory recognition strengthens clinical confidence and commercial adoption. These evolving frameworks encourage continuous investment in assay standardization, analytical performance, and post-market evidence generation. Healthcare providers consequently gain greater confidence in incorporating MSI testing into routine treatment pathways.

Market Restraints

• Limited access to advanced molecular diagnostic infrastructure continues to restrict MSI testing adoption in resource-constrained healthcare systems.

• Variability in reimbursement coverage across countries slows routine implementation despite growing clinical evidence supporting biomarker-guided therapy.

• Differences in laboratory methodologies and interpretation criteria continue to create challenges for assay standardization and result comparability.

Market Opportunities

• Expansion into Additional Solid Tumor Indications: Clinical evidence increasingly supports MSI assessment beyond colorectal and endometrial cancers. Researchers are evaluating biomarker utility across pancreatic, prostate, ovarian, gastric, and other malignancies because immunotherapy indications continue expanding. Diagnostic developers are validating assays across broader tumor populations to address this emerging clinical demand.

• Development of Liquid Biopsy-Based MSI Testing: Conventional tissue biopsies remain challenging for many patients because adequate tumor material is not always available. Developers are advancing circulating tumor DNA-based MSI assays to provide a minimally invasive molecular assessment. These technologies support serial disease monitoring while expanding testing accessibility. Continued clinical validation is positioning liquid biopsy as a complementary approach to tissue-based diagnostics.

• Integration of Artificial Intelligence and Advanced Bioinformatics: Increasing genomic data complexity requires scalable interpretation tools that support clinical decision-making. Diagnostic companies are incorporating artificial intelligence-enabled bioinformatics into molecular analysis platforms to improve reporting accuracy and workflow efficiency. These capabilities reduce analytical variability while facilitating standardized interpretation across laboratories. The resulting automation strengthens laboratory productivity and supports broader implementation of precision oncology diagnostics.

Disease & Epidemiology Analysis

MSI represents a molecular phenotype resulting from defects in the DNA mismatch repair (MMR) system, leading to the accumulation of insertion and deletion mutations within microsatellite regions of the genome. Deficient mismatch repair (dMMR) promotes genomic instability, generating a high neoantigen burden that enhances tumor immunogenicity and increases responsiveness to immune checkpoint inhibitors. This biological mechanism establishes MSI testing as both a prognostic and predictive biomarker across multiple solid tumors.

The clinical demand for MSI testing is expanding because precision oncology guidelines increasingly recommend molecular characterization at diagnosis or before treatment selection. Colorectal cancer remains the largest application area, where MSI testing supports Lynch syndrome screening, prognostic assessment, and immunotherapy eligibility. Endometrial cancer is also experiencing increasing testing adoption because universal MMR or MSI screening is becoming integrated into routine pathological evaluation. Gastric, ovarian, pancreatic, and prostate cancers are contributing to incremental demand as clinical studies continue demonstrating therapeutic relevance for selected patient populations.

Advances in sequencing technologies are also expanding the epidemiological understanding of MSI across less common malignancies. Large-scale genomic profiling initiatives are identifying low-frequency MSI-H populations in the biliary tract, small bowel, neuroendocrine, and other rare tumors, creating opportunities for tissue-agnostic therapeutic strategies. Healthcare systems are therefore integrating standardized MSI testing into broader molecular profiling programs to improve patient identification and facilitate equitable access to biomarker-guided therapies.

Treatment Guidelines Landscape

Market Segmentation

By Product

Kits and reagents constitute the largest demand segment because every MSI analysis requires validated consumables, irrespective of the testing platform. Clinical laboratories are increasingly adopting standardized reagent kits that simplify workflow validation while improving analytical reproducibility. Regulatory expectations for assay consistency continue to encourage laboratories to utilize commercially validated products instead of laboratory-developed tests where appropriate. Manufacturers are expanding reagent portfolios compatible with PCR, capillary electrophoresis, and next-generation sequencing platforms to accommodate diverse laboratory requirements. This recurring consumable demand creates stable revenue opportunities while supporting broader implementation of precision oncology diagnostics.

By Cancer Type

Colorectal cancer represents the primary clinical application for MSI testing because international treatment guidelines recommend universal assessment for newly diagnosed patients. Healthcare providers are increasingly integrating MSI status into routine diagnostic pathways because it simultaneously supports Lynch syndrome screening, prognostic evaluation, and immunotherapy selection. Pharmaceutical evidence continues demonstrating improved treatment outcomes among patients with MSI-high metastatic disease receiving immune checkpoint inhibitors. Diagnostic manufacturers are consequently prioritizing colorectal cancer during assay validation studies and companion diagnostic development. This established clinical utility sustains colorectal cancer as the largest demand contributor within the MSI testing market.

By Clinical Application

Companion diagnostics are becoming the fastest-evolving application because oncology drug development increasingly depends on validated predictive biomarkers. Pharmaceutical companies are incorporating MSI testing throughout clinical development programs to identify patients most likely to respond to immunotherapy. Regulatory agencies continue requiring robust analytical evidence linking diagnostic performance with therapeutic efficacy for biomarker-directed treatments. Diagnostic companies are strengthening strategic partnerships with drug developers to achieve synchronized regulatory submissions and commercial launches. These collaborations position companion diagnostics as a central driver of future MSI testing demand.

Regional Analysis

North America Market Analysis

North America maintains the largest share of the MSI testing market because precision oncology has become deeply integrated into routine clinical practice. Universal biomarker testing recommendations for colorectal and endometrial cancers continue supporting high testing volumes across academic medical centers, integrated health systems, and reference laboratories. Pharmaceutical companies are increasingly conducting biomarker-driven immunotherapy trials throughout the United States and Canada, strengthening demand for validated companion diagnostics. The region also benefits from extensive molecular diagnostic infrastructure, high adoption of NGS technologies, and strong collaboration between diagnostic manufacturers and biotechnology companies. Regulatory support from the U.S. Food and Drug Administration has accelerated commercialization of companion diagnostics, while reimbursement pathways continue encouraging incorporation of molecular testing into standard oncology care.

Europe Market Analysis

European demand continues to expand because harmonized precision medicine initiatives are encouraging broader molecular characterization across multiple cancer types. Countries including Germany, France, the United Kingdom, Italy, and Spain are strengthening genomic medicine programs through investments in molecular pathology infrastructure and national cancer strategies. Healthcare providers are increasingly integrating MSI testing alongside broader genomic profiling to improve immunotherapy selection and hereditary cancer assessment. Pharmaceutical collaborations with European cancer research networks continue to increase multicenter clinical validation studies, supporting regulatory submissions across multiple jurisdictions.

Asia Pacific Market Analysis

Asia Pacific is experiencing the fastest growth because governments are expanding precision medicine infrastructure while cancer incidence continues increasing throughout the region. Japan and South Korea have established advanced molecular diagnostics ecosystems that increasingly incorporate MSI testing into oncology care. China is investing heavily in genomic sequencing capacity, hospital molecular laboratories, and domestic companion diagnostic development. India, Australia, Singapore, and several Southeast Asian countries are strengthening access to molecular pathology services through public and private healthcare investments. Pharmaceutical companies are simultaneously expanding regional oncology clinical trials that require biomarker-defined patient populations.

Rest of the World

Demand across Latin America, the Middle East, and Africa remains comparatively lower but continues improving as precision oncology capabilities expand. Brazil, Mexico, Saudi Arabia, and the United Arab Emirates are investing in tertiary oncology centers capable of performing advanced molecular diagnostics. International collaborations with pharmaceutical companies and academic institutions are increasing access to biomarker-driven clinical trials, encouraging the adoption of standardized MSI testing protocols. Resource limitations continue restricting widespread implementation in several lower-income countries because molecular infrastructure, reimbursement coverage, and specialized workforce capacity remain uneven.

Regulatory Landscape

The regulatory framework for MSI testing is evolving from laboratory validation requirements toward integrated biomarker-drug approval pathways. Regulatory agencies recognize MSI-high (MSI-H) and deficient mismatch repair (dMMR) as clinically validated predictive biomarkers for immune checkpoint inhibitor therapy, making molecular diagnostics an essential component of precision oncology. This approach has increased regulatory emphasis on analytical validity, clinical validity, and standardized reporting because treatment eligibility depends directly on reliable biomarker assessment. Diagnostic manufacturers are therefore expanding multicenter validation studies and quality management systems to satisfy increasingly rigorous approval requirements.

The U.S. Food and Drug Administration (FDA) continues supporting biomarker-driven oncology through tissue-agnostic approvals that rely on MSI-H or dMMR status rather than tumor origin. This regulatory model has encouraged pharmaceutical companies to incorporate companion diagnostics early in clinical development, while diagnostic manufacturers are pursuing synchronized regulatory submissions alongside therapeutic products. The FDA also encourages the use of validated companion diagnostics whenever specified in product labeling, strengthening commercial demand for standardized MSI assays.

Pipeline Analysis

The MSI testing pipeline is increasingly evolving alongside immuno-oncology drug development because patient selection has become a major determinant of clinical trial success. Pharmaceutical sponsors are incorporating MSI biomarkers into Phase I through Phase III studies evaluating programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and novel immune-modulating therapies. This strategy reduces biological heterogeneity within study populations while improving the probability of demonstrating clinically meaningful treatment benefit. Diagnostic developers are simultaneously validating companion assays capable of generating reproducible MSI results across diverse laboratory environments, ensuring regulatory readiness before therapeutic approval.

Mechanistically, MSI-high tumors accumulate insertion and deletion mutations because deficient mismatch repair prevents the correction of DNA replication errors. This process substantially increases tumor mutational burden and neoantigen formation, making malignant cells more recognizable to the immune system. Combination regimens incorporating CTLA-4 inhibitors, cytokine modulators, cancer vaccines, bispecific antibodies, and cellular immunotherapies are also being evaluated to improve responses among patients who demonstrate primary or acquired resistance to checkpoint blockade. As these therapeutic approaches continue progressing through clinical development, MSI testing is becoming an increasingly important biomarker for enrollment and response prediction.

Reimbursement Landscape

Reimbursement remains one of the most influential determinants of MSI testing adoption because molecular diagnostics directly affect treatment selection for high-cost immunotherapies. Healthcare payers increasingly recognize the clinical value of biomarker-guided therapy as it reduces unnecessary treatment exposure while improving patient outcomes. Coverage decisions are therefore expanding for guideline-recommended indications, particularly colorectal and endometrial cancers, where international clinical societies support universal testing. Laboratories consequently experience greater confidence in implementing standardized MSI assays when reimbursement pathways align with evidence-based treatment recommendations.

The United States currently demonstrates the most mature reimbursement environment through Medicare and commercial payer coverage for clinically indicated molecular testing. Several European healthcare systems also reimburse MSI testing when recommended by national treatment guidelines, although reimbursement criteria continue to vary across member states. Countries throughout the Asia-Pacific are gradually incorporating precision oncology diagnostics into public healthcare reimbursement frameworks, but access remains heterogeneous because funding policies differ significantly between jurisdictions.

Competitive Landscape

Agilent Technologies, Inc.

Agilent Technologies, Inc. is strengthening its position in the MSI testing market through its integrated pathology and molecular diagnostics portfolio, including Dako immunohistochemistry (IHC) assays and genomics solutions that support mismatch repair (MMR) assessment. The company's Diagnostics and Genomics segment remains a key contributor to its business, and recent investments in digital pathology and companion diagnostic collaborations continue expanding its precision oncology capabilities.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. maintains a leading position in precision oncology by combining pharmaceutical expertise with advanced tissue diagnostics. Its VENTANA MMR IHC assays, cobas molecular platforms, and companion diagnostic portfolio support biomarker-guided cancer treatment, while ongoing collaborations with pharmaceutical partners continue strengthening its role in immuno-oncology.

QIAGEN N.V.

QIAGEN N.V. focuses on molecular diagnostics and companion diagnostic development through its sample preparation technologies, QIAcuity digital PCR systems, QIAseq sequencing solutions, and therascreen portfolio. The company continues expanding collaborations with pharmaceutical manufacturers to support biomarker-driven oncology clinical trials and precision medicine initiatives.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. supports MSI testing through its Ion Torrent sequencing platforms, Oncomine assays, PCR technologies, and clinical bioinformatics solutions that enable comprehensive genomic profiling. The company continues strengthening its precision oncology portfolio by expanding companion diagnostic partnerships and developing integrated sequencing workflows for clinical laboratories.

Illumina, Inc.

Illumina, Inc. remains a global leader in next-generation sequencing by providing NovaSeq, NextSeq, MiSeq, TruSight Oncology assays, and DRAGEN bioinformatics software that facilitate integrated MSI analysis. The company continues investing in oncology sequencing and clinical genomics to support comprehensive biomarker profiling across precision oncology applications.

Guardant Health

Guardant Health differentiates itself through liquid biopsy technologies that enable non-invasive comprehensive genomic profiling, including MSI assessment in advanced cancers using the Guardant360 platform. The company continues expanding its precision oncology portfolio following the FDA approval of its Shield™ blood test while advancing liquid biopsy applications through pharmaceutical collaborations and clinical validation programs.

Key Developments

• November 2025: The U.S. Food and Drug Administration (FDA) approved the Promega OncoMate MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; not MSI-high) endometrial carcinoma who may benefit from treatment with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, plus LENVIMA (lenvatinib).

Strategic Insights and Future Market Outlook

MSI testing is transitioning from a single biomarker assay to a core component of comprehensive genomic profiling because precision oncology increasingly depends on simultaneous assessment of multiple predictive biomarkers. Diagnostic manufacturers are expanding NGS-enabled workflows, automation technologies, and bioinformatics platforms to improve laboratory efficiency while supporting broader immunotherapy adoption. Pharmaceutical sponsors are also integrating MSI into earlier stages of clinical development, strengthening demand for validated companion diagnostics across multiple tumor types.

Regulatory harmonization, expanding reimbursement for biomarker-guided therapies, and increasing clinical evidence supporting tissue-agnostic treatment strategies are expected to sustain long-term market growth. Future competition will depend less on standalone assay performance and more on integrated diagnostic ecosystems that combine molecular testing, digital pathology, artificial intelligence-assisted interpretation, and strategic pharmaceutical collaborations. Companies capable of delivering scalable, standardized, and globally compliant precision oncology solutions are likely to strengthen their competitive positions during the forecast period.

The MSI testing market continues evolving alongside advances in cancer immunotherapy and molecular diagnostics. Growing adoption of precision medicine, expanding clinical trial activity, and continued investment in companion diagnostics are reinforcing the strategic importance of MSI testing across oncology care.

MSI Testing Market Scope: